Author Archive

Organization & Key People

Trial Steering Committee comprises : Principle Investigator: Dr. Christopher Chen National Coordinators: Singapore: Dr.N.V.Ramani Philippines: Dr. Jose Navarro Thailand: Dr. NiphonPoungvarin Hong kong: Dr. Lawrence Wong Srilanka: Dr. Asita de Silva Malaysia: Dr.EowGaik Bee Data Monitoring Safety Board (DMSB) is chaired by Prof G. Donnan and the members are Prof C. Tzourio and Prof D. […]


Dr. Bernard Chan National University Hospital Dr. Bernard Chan is a Consultant at the National University Hospital of Singapore. He is a member of Stroke Disease Management Group and Singapore Stroke Registry Committee. His main fields of investigation are Neurosonology in the evaluation of extraclinical and intraclinical artery disease, Thrombolytic therapy in acute ischaemic stroke […]

XVII European Stroke Conference

Nice-Acropolis, FranceMay 13-16, 2008

5th Asia Pacific Conference Against Stroke

Crowne Plaza Hotel, Ortigas Center, Pasig City, PhilippinesMarch 13-16, 2008

About NeuroAiD™

NeuroAiD was first known a Traditional Chinese Medicine drug marketed in China for approved-indication of cerebral infarction’s functional and neurological deficits, i.e. helping patient recover from their disabilities after a stroke.

Clinical Data on NeuroAiD™

Two clinical studies were implemented in 1999-2000 in China. The clinical studies conducted in China, were double-blind controlled clinical trials where NeuroAiD efficacy was assessed versus another Traditional Chinese Medicine (TCM) proven to be superior to Citicoline in separate trials.

Other Clinical Research

In 2005-06, three additional safety trials were implemented on NeuroAiD™. The conclusion of these studies is that NeuroAiD™ can safely be administered without modification of hematological and bio-chemical parameters. Below is an abstract of the scientific paper written after completion of studies, this paper has undergone peer-review process and will be published in the Cerebrovascular […]

Clinical Research

We identified in China a promising natural drug known as NeuroAiD internationally for which data from research conducted in China shows a high efficacy in improving stroke rehabilitation, even at a late stage (subjects started treatment 2 weeks to 6 months after their stroke).

CHIMES Protocol

CHIMES protocol was published in march 2009 in the International Journal of Stroke

CHIMES Extension (CHIMES-E) Protocol

The CHIMES-E protocol was published in March 2013 in Cerebrovascular Diseases